Daiichi Sankyo anticoagulant gets nod in UK; GSK's Breo approved for Canada;

@FiercePharma: $GSK rehires former China government affairs director Shi. FiercePharmaAsia story | Follow @FiercePharma

@EricPFierce: ICYMI: #FDA may add Baxter #saline Mexico plant to US supply. Now if Baxter can just quit having to recall saline. More | Follow @EricPFierce

@CarlyHFierce: What was summer before I covered takeover battles? | Follow @CarlyHFierce

> Daiichi Sankyo's new blood thinner Lixiana has been recommended for a second indication in England to prevent stroke and systemic embolism in adults with non-valvular atrial fibrillation. Story

> Taro Pharmaceuticals ($TARO) reported increased revenues for the second quarter. Release

> GlaxoSmithKline ($GSK) and Theravance ($THRX) on Thursday announced the approval in Canada of Breo Ellipta for the once-daily maintenance treatment of asthma in patients aged 18 years and older with reversible obstructive airways disease. Release

Medical Device News

@FierceMedDev: Updated w/ info from $MDT: Medtronic recalls CoreValve TAVR component due to presence of particulate matter. Story | Follow @FierceMedDev

@VarunSaxena2: FDA issues warning on heart pump safety issues: strokes, blood clots and bleeding. Article | Follow @VarunSaxena2

@EmilyWFierce: ICYMI from FiercePharma: British watchdog cracks down on Pfizer for huge price hikes on epilepsy drug. Story | Follow @EmilyWFierce

> TAVR maker JenaValve receives $26.5M to fund U.S. studies. Report

> DexCom ups 2015 guidance but doesn't aim for profit; plans next-gen launches this year, in 2017. Story

> Cardinal scores $1B DOD contract as dealmaking delivers growth. Article

Biotech News

@FierceBiotech: Pfizer takes the lead in another hot immuno-oncology contest. Report | Follow @FierceBiotech

@JohnCFierce: Tick tock--Fierce 15 noms deadline is approaching. More | Follow @JohnCFierce

@DamianFierce: Probably the best thing about having lots of money is how it turns itself into even more money. Story | Follow @DamianFierce

> Decimated by clinical failure, Xoma turns to plan B. More

> NantKwest's record-setting IPO heaps another billion on Soon-Shiong's fortune. Story

> Sanofi deepens its Evotec ties with a $330M diabetes deal. Article

Suggested Articles

AbbVie has seen blossoming market share for immunology launches Rinvoq and Skyrizi—and it's eyeing Allergan's neurology biz for a boost, too.

While Novo's Rybelsus launch has slowed due to the pandemic, another version of the med, Ozempic posted strong sales.

AZ sold Atacand and Atacand Plus rights in about 70 countries to Cheplapharm.